rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

ProQR Therapeutics N.V. -

PRQR · Nasdaq

Health CareBiotechnologyNot moving yet

PRQR stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 24.7% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$2.7M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
68 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.1MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Boer Daniel Anton DeChief Executive Officerbought200,000at $1.7731 Jul 2026filed 3 Aug 2026
Bart FiliusDirectorbought150,000at $1.7217 Jul 2026filed 21 Jul 2026
Boer Daniel Anton DeChief Executive Officerbought150,000at $1.749 Jul 2026filed 13 Jul 2026
Boer Daniel Anton DeChief Executive Officerbought150,000at $1.597 Jul 2026filed 8 Jul 2026
Bart FiliusDirectorbought150,000at $1.5426 Jun 2026filed 30 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders68+2 on the quarter
New · exited13 · 12
Reported value$111.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ADAGE CAPITAL PARTNERS GP, L.L.C.added · filed 14 Aug 20269,015,897$16.8M+2,762,430+44.2%
Aberdeen Group plcadded · filed 31 Jul 20268,932,507$16.6M+5,615,542+169.3%
Affinity Asset Advisors, LLCadded · filed 13 Aug 20265,543,936$10.3M+3,089,658+125.9%
Privium Fund Management B.V.added · filed 7 Aug 20265,520,024$10.3M+52,875+1.0%
Ikarian Capital, LLCadded · filed 14 Aug 20263,425,930$6.4M+1,933,701+129.6%
Woodline Partners LPnew · filed 14 Aug 20263,277,143$6.1M+3,277,143
HEIGHTS CAPITAL MANAGEMENT, INCnew · filed 14 Aug 20262,762,430$5.1M+2,762,430
MORGAN STANLEYadded · filed 13 Aug 20261,767,215$3.3M+467,440+36.0%
SPHERA FUNDS MANAGEMENT LTD.new · filed 14 Aug 20261,757,458$3.3M+1,757,458
Kynam Capital Management, LPunchanged · filed 14 Aug 20261,566,317$2.9M00.0%
31 Mar 2023 – 30 Jun 2026
415772Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Daniel Anton de Boer Company insiderChief Executive Officer · last 31 Jul 20263 · 0
Bart Filius Company insiderDirector · last 17 Jul 20262 · 0
Gylvin Lykke Hinsch Company insiderDirector · last 2 Jun 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 31 Dec 20250.1%

Analyst forecasts

No analyst forecasts yet.